Personalized Medicine Coalition Applauds NIH Nomination
Washington, DC - July 8, 2009 — The Personalized Medicine Coalition (PMC) today applauded President Obama’s nomination of Francis S. Collins, M.D., Ph.D., a physician-geneticist noted for his landmark discoveries of disease genes and as the leader of the U.S. government effort to map the human genome and to incorporate genetics into medicine, to be director of the National Institutes of Health.
As Director of the National Human Genome Research Institute of the National Institutes of Health from 1993 to 2008, Dr. Collins spearheaded the international effort to sequence the 3 billion letters of DNA code, a goal that was completed in 2003. As the keynote speaker at PMC’s first Annual State of Personalized Medicine conference in 2005, Dr. Collins predicted that the era of the human genome would usher in a health care revolution. “People are always talking about personalized medicine as part of the distant future, but I think it’s here now,” he said. A proponent of personalized medicine, he has understood and advocated the alignment of science, policy and education to improve patients’ lives.
“The selection of Dr. Collins is an excellent decision because he is a superb administrator and creative scientist,” said PMC Board member Patrick F. Terry, president of Technic Solutions in Chevy Chase, Md. “His communication and leadership abilities will facilitate innovative approaches to biomedical research and the advancement of personalized medicine.”
As director of NIH, Dr. Collins would take over an agency that is a key to the president’s plans for revamping the nation’s healthcare. The 27 institutes and centers under the NIH umbrella employ more than 18,000 people and spend some $28 billion a year on research, including work conducted at thousands of universities and medical schools across the country.
Dr. Collins has helped lay the foundation for 21st century medicine, said Edward Abrahams, Ph.D., PMC’S Executive Director.
“Through his leadership, we have indeed entered the genomic age, and are on the way towards realizing the revolution that will change healthcare in the future,” Dr. Abrahams said. He noted that there are 37 personalized-medicine products on the market today, representing a translation of new science into improved clinical care. “Dr. Collins’ commitment to patients’ health has defined his life’s work as a physician and scientist. As director of NIH he will undoubtedly continue his efforts to improve healthcare in this country,” Dr. Abrahams said.
Personalized medicine represents a shift from the traditional one-size-fits-all approach in therapeutic selection to more precise treatments that are tailored for individuals based on their molecular makeup.
Elizabeth Schwinn (firstname.lastname@example.org)
Personalized Medicine Coalition
About the Personalized Medicine Coalition
The Personalized Medicine Coalition (PMC), representing a broad spectrum of academic, industrial, patient, provider, and payer communities, seeks to advance the understanding and adoption of personalized medicine concepts and products for the benefit of patients. For more information on the Personalized Medicine Coalition, please visit www.PersonalizedMedicineCoalition.org.